Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.

JR, Brown; J, Moslehi; S, O'Brien; P, Ghia; P, Hillmen; F, Cymbalista; TD, Shanafelt; G, Fraser; S, Rule; TJ, Kipps; S, Coutre; MS, Dilhuydy; P, Cramer; A, Tedeschi; U, Jaeger; M, Dreyling; JC, Byrd; A, Howes; M, Todd; J, Vermeulen; DF, James; F, Clow; L, Styles; R, Valentino; M, Wildgust; M, Mahler; JA, Burger

doi:10.3324/haematol.2017.171041

Public

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.

Shared by NobleBlocks on Jul 27, 2017 • 12:00 AM UTC

Authors:

Brown JR

Moslehi J

O'Brien S

Abstract

The first-in-class Bruton's tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cell malignancies; however, atrial fibrillation (AF) has been reported in 6-16% of ibrutinib patients. We pooled data from 1505 chronic lymphocytic leukemia and mantle cell lymphoma patients enrolled in ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!